Drug intelligence / Profile preview

Chaigetuire Keli

Development stage: Unknown
Lead developer: Beijing Kaijin Technology
Administration: Oral

Overview

Chaigetuire Keli is a Traditional Chinese Medicine (TCM) granule formulation developed by Beijing Kaijin Technology for the treatment of the common cold. It is specifically indicated for the "exterior cold with interior heat" pattern (表寒里热证), a diagnostic category in TCM characterized by symptoms such as fever, chills, and sore throat. The name suggests the inclusion of *Bupleurum* (Chai Hu) and *Pueraria* (Ge Gen), which are traditionally utilized for their antipyretic and diaphoretic effects. The drug is currently in Phase 2 clinical development in China, with trials focusing on dose exploration and the preliminary evaluation of safety and efficacy.

Brand names: Chaigetuire Keli
Other names: Chaigetuire Granules柴葛退热颗粒

Targets

SCN5A (Sodium channel protein type 5 subunit alpha)

Beyond the preview

Go deeper on Chaigetuire Keli.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chaigetuire Keli.

Explore the full profile